<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720210</url>
  </required_header>
  <id_info>
    <org_study_id>18-004450</org_study_id>
    <nct_id>NCT03720210</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis</brief_title>
  <official_title>Pilot Study for Treatment of Amiodarone-Induced Thyroiditis With Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators intend to study the changes in thyroid hormone storage and production in&#xD;
      amiodarone-induced thyrotoxicosis patients after RFA therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to identify patients with amiodarone-induced thyrotoxicosis (AIT) that&#xD;
      failed to respond to medical therapy or have developed side effects from medical therapy or&#xD;
      are considered high risk for such therapy.&#xD;
&#xD;
      These patients will be offered the option to undergo radiofrequency ablation (RFA) of a&#xD;
      portion of the thyroid gland in order to decrease thyroid hormone production and/or to&#xD;
      inactive the existing thyroid hormone store before their leakage into the circulation.&#xD;
&#xD;
      Investigators will follow these patients to assess their clinical response as well as their&#xD;
      thyroid values. The safety of the procedure will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very low enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label single interventional series</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Free T4 Response Post RFA</measure>
    <time_frame>3 - 6 months</time_frame>
    <description>Thyroid tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total T3 Response Post RFA</measure>
    <time_frame>3 - 6 months</time_frame>
    <description>Thyroid tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Related to RFA Procedure</measure>
    <time_frame>1 - 2 months</time_frame>
    <description>McGill Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid-stimulating Hormone (TSH) Response Post RFA</measure>
    <time_frame>3 - 6 months</time_frame>
    <description>Thyroid tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Amiodarone-Induced Thyrotoxicosis</condition>
  <arm_group>
    <arm_group_label>RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RFA</intervention_name>
    <description>Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
    <arm_group_label>RFA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are adults&#xD;
&#xD;
          -  Have overt thyrotoxicosis (within 2 weeks prior to enrollment)&#xD;
&#xD;
          -  Are receiving medical therapy for AIT&#xD;
&#xD;
          -  Are able to understand the study procedures and to comply with them for the entire&#xD;
             length of the study&#xD;
&#xD;
          -  Have not normalized their thyroid levels after one month of standard therapy or&#xD;
&#xD;
          -  Have persistent and clinically significant thyrotoxicosis (less than 25% decrease in&#xD;
             T4 value or patients requiring hospitalization with Congestive heart failure (CHF),&#xD;
             tachyarrhythmias, hemodynamic instability or similar co-morbidities) after 2 weeks of&#xD;
             standard therapy where additional medical therapy is deemed unlikely to be beneficial&#xD;
             or with high risk of side-effects (e.g. hepatotoxicity of antithyroid medications,&#xD;
             agranulocytosis of potassium perchlorate or ATD or fluid retention associated with&#xD;
             steroids).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with prior neck surgery or neck radiation&#xD;
&#xD;
          -  Patients with neck anatomy that precludes easy access by RFA to the entirety of&#xD;
             thyroid parenchyma&#xD;
&#xD;
          -  Patients on anticoagulation therapy&#xD;
&#xD;
          -  Patients with comorbidities deemed too high of a risk for general anesthesia&#xD;
&#xD;
          -  Treatment with another investigational drug or intervention (within 6 weeks of planned&#xD;
             RFA).&#xD;
&#xD;
          -  Current drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Inability or unwillingness of individual or legal guardian/representative to give&#xD;
             written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marius N Stan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <results_first_submitted>September 11, 2021</results_first_submitted>
  <results_first_submitted_qc>September 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2021</results_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Marius Stan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hyperthyroidism</keyword>
  <keyword>RFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyrotoxicosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03720210/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RFA Group</title>
          <description>RFA (Radiofrequency Ablation)&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RFA Group</title>
          <description>RFA&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Free T4 Response Post RFA</title>
        <description>Thyroid tests</description>
        <time_frame>3 - 6 months</time_frame>
        <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RFA Group</title>
            <description>RFA&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
          </group>
        </group_list>
        <measure>
          <title>Free T4 Response Post RFA</title>
          <description>Thyroid tests</description>
          <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total T3 Response Post RFA</title>
        <description>Thyroid tests</description>
        <time_frame>3 - 6 months</time_frame>
        <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RFA Group</title>
            <description>RFA&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
          </group>
        </group_list>
        <measure>
          <title>Total T3 Response Post RFA</title>
          <description>Thyroid tests</description>
          <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Related to RFA Procedure</title>
        <description>McGill Pain Questionnaire</description>
        <time_frame>1 - 2 months</time_frame>
        <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RFA Group</title>
            <description>RFA&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Related to RFA Procedure</title>
          <description>McGill Pain Questionnaire</description>
          <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thyroid-stimulating Hormone (TSH) Response Post RFA</title>
        <description>Thyroid tests</description>
        <time_frame>3 - 6 months</time_frame>
        <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RFA Group</title>
            <description>RFA&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
          </group>
        </group_list>
        <measure>
          <title>Thyroid-stimulating Hormone (TSH) Response Post RFA</title>
          <description>Thyroid tests</description>
          <population>The one subject enrolled did not return for follow up. Data not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from RFA procedure to 72 hours post RFA procedure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RFA Group</title>
          <description>RFA&#xD;
RFA: Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of interested &amp; suitable candidates. The one subject enrolled was lost to follow up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marius N. Stan, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-3769</phone>
      <email>Stan.Marius@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

